132 related articles for article (PubMed ID: 21527297)
21. In vitro effect of temperature on phagocytic and cytotoxic activities of splenic phagocytes of the wall lizard, Hemidactylus flaviviridis.
Mondal S; Rai U
Comp Biochem Physiol A Mol Integr Physiol; 2001 Jun; 129(2-3):391-8. PubMed ID: 11423311
[TBL] [Abstract][Full Text] [Related]
22. Neuropeptide Y modulates functions of inflammatory cells in the rat: distinct role for Y1, Y2 and Y5 receptors.
Mitić K; Stanojević S; Kuštrimović N; Vujić V; Dimitrijević M
Peptides; 2011 Aug; 32(8):1626-33. PubMed ID: 21699939
[TBL] [Abstract][Full Text] [Related]
23. Intracellular signaling mechanisms mediating catecholamine release upon activation of NPY Y1 receptors in mouse chromaffin cells.
Rosmaninho-Salgado J; Araújo IM; Alvaro AR; Duarte EP; Cavadas C
J Neurochem; 2007 Nov; 103(3):896-903. PubMed ID: 17868303
[TBL] [Abstract][Full Text] [Related]
24. Neuropeptide Y regulates rat renal tubular Na,K-ATPase through several signalling pathways.
Ohtomo Y; Ono S; Zettergren E; Sahlgren B
Acta Physiol Scand; 1996 Sep; 158(1):97-105. PubMed ID: 8876753
[TBL] [Abstract][Full Text] [Related]
25. Progesterone secretion by luteinizing human granulosa cells: a possible cAMP-dependent but PKA-independent mechanism involved in its regulation.
Chin EC; Abayasekara DR
J Endocrinol; 2004 Oct; 183(1):51-60. PubMed ID: 15525573
[TBL] [Abstract][Full Text] [Related]
26. The cyclic AMP-dependent protein kinase A pathway is involved in progesterone effects on calcitonin secretion from TT cells.
Lu CC; Tsai SC
Life Sci; 2007 Oct; 81(19-20):1411-20. PubMed ID: 17963787
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of neuropeptide Y on cyclic AMP accumulation in slices of the nucleus tractus solitarius region of the rat.
Härfstrand A; Fredholm B; Fuxe K
Neurosci Lett; 1987 May; 76(2):185-90. PubMed ID: 3035437
[TBL] [Abstract][Full Text] [Related]
28. Identification of a receptor protein for neuropeptide Y in rabbit kidney. G-protein association and inhibition of adenylate cyclase.
Gimpl G; Wahl J; Lang RE
FEBS Lett; 1991 Feb; 279(2):219-22. PubMed ID: 1848189
[TBL] [Abstract][Full Text] [Related]
29. Effect of cAMP elevation on the NPY gene transcription.
Pance A; Balbi D; Holliday N; Allen JM
Biochem Soc Trans; 1995 Feb; 23(1):47S. PubMed ID: 7538948
[No Abstract] [Full Text] [Related]
30. Neuropeptide Y inhibits forskolin-stimulated adenylate cyclase in bovine adrenal chromaffin cells via a pertussis toxin-sensitive process.
Zhu J; Li W; Toews ML; Hexum TD
J Pharmacol Exp Ther; 1992 Dec; 263(3):1479-86. PubMed ID: 1335068
[TBL] [Abstract][Full Text] [Related]
31. Involvement of cAMP/cAMP-dependent protein kinase signaling pathway in regulation of Na+,K+-ATPase upon activation of opioid receptors by morphine.
Wu ZQ; Li M; Chen J; Chi ZQ; Liu JG
Mol Pharmacol; 2006 Mar; 69(3):866-76. PubMed ID: 16317112
[TBL] [Abstract][Full Text] [Related]
32. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation.
D'Angelo G; Lee H; Weiner RI
J Cell Biochem; 1997 Dec; 67(3):353-66. PubMed ID: 9361190
[TBL] [Abstract][Full Text] [Related]
33. Neuropeptide Y (18-36) is a competitive antagonist of neuropeptide Y in rat cardiac ventricular membranes.
Balasubramaniam A; Sheriff S
J Biol Chem; 1990 Sep; 265(25):14724-7. PubMed ID: 2168390
[TBL] [Abstract][Full Text] [Related]
34. cAMP cascade (PKA, Epac, adenylyl cyclase, Gi, and phosphodiesterases) regulates myelin phagocytosis mediated by complement receptor-3 and scavenger receptor-AI/II in microglia and macrophages.
Makranz C; Cohen G; Reichert F; Kodama T; Rotshenker S
Glia; 2006 Mar; 53(4):441-8. PubMed ID: 16345030
[TBL] [Abstract][Full Text] [Related]
35. Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor.
Lecat S; Belemnaba L; Galzi JL; Bucher B
Cell Signal; 2015 Jul; 27(7):1297-304. PubMed ID: 25817573
[TBL] [Abstract][Full Text] [Related]
36. Neuropeptide Y reduces macromolecule permeability of coronary endothelial monolayers.
Noll T; Hempel A; Piper HM
Am J Physiol; 1996 Nov; 271(5 Pt 2):H1878-83. PubMed ID: 8945904
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of dopamine mediated inhibition of neuropeptide Y release from pheochromocytoma cells (PC12 cells).
Cao G; Gardner A; Westfall TC
Biochem Pharmacol; 2007 May; 73(9):1446-54. PubMed ID: 17286966
[TBL] [Abstract][Full Text] [Related]
38. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo.
Mullins D; Kirby D; Hwa J; Guzzi M; Rivier J; Parker E
Mol Pharmacol; 2001 Sep; 60(3):534-40. PubMed ID: 11502885
[TBL] [Abstract][Full Text] [Related]
39. Neuropeptide Y modulates ATP-induced increases in internal calcium via the adenylate cyclase/protein kinase A system in a human neuroblastoma cell line.
Soares Lemos V; Bucher B; Takeda K
Biochem J; 1997 Jan; 321 ( Pt 2)(Pt 2):439-44. PubMed ID: 9020878
[TBL] [Abstract][Full Text] [Related]
40. Effects of differentiation on neuropeptide-Y receptors and responses in rat pheochromocytoma cells.
DiMaggio DA; Farah JM; Westfall TC
Endocrinology; 1994 Feb; 134(2):719-27. PubMed ID: 8299567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
